Alnylam Pharmaceuticals, Inc. (LON: 0HD2)

Market Cap	27.91B
Revenue (ttm)	1.56B
Net Income (ttm)	-247.90M
Shares Out	n/a
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,398
Average Volume	824
Open	265.71
Previous Close	255.79
Day's Range	260.00 - 268.46
52-Week Range	143.66 - 268.46
Beta	n/a
RSI	64.03
Earnings Date	Feb 20, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

In 2023, Alnylam Pharmaceuticals's revenue was $1.83 billion, an increase of 76.23% compared to the previous year's $1.04 billion. Losses were -$440.24 million, -61.08% less than in 2022.

Financial numbers in USD